Zomig-ZMT

See also: Generic Zomig

Zomig-ZMT is a brand name of zolmitriptan, approved by the FDA in the following formulation(s):

ZOMIG-ZMT (zolmitriptan - tablet, orally disintegrating; oral)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: February 13, 2001
  
  Strength(s): 2.5MG
  


• 
  Manufacturer: ASTRAZENECA
  
  Approval date: September 17, 2001
  
  Strength(s): 5MG ^[RLD]

Has a generic version of Zomig-ZMT been approved?

No. There is currently no therapeutically equivalent version of Zomig-ZMT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zomig-ZMT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Indolyl compounds for treating migraine
  Patent 5,466,699
  Issued: November 14, 1995
  Inventor(s): Robertson; Alan D. & Hill; Alan P. & Glen; Robert C. & Martin; Graeme R.
  Assignee(s): Burroughs Wellcome Co.
  ##STR1## The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C.sub.1-4 alkyl, X is --O--, --S--, --NH--, or --CH.sub.2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R.sup.1 and R.sup.2 are independently selected from hydrogen and C.sub.1-4 alkyl and R.sup.3 is hydrogen or C.sub.1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.
  
  Patent expiration dates:
  
  
  • November 14, 2012
    
  
  
  
  • May 14, 2013
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Zomig ZMT Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Zomig-ZMT Consumer Information (Cerner Multum)
• Zomig-ZMT Advanced Consumer Information (Micromedex)
• Zolmitriptan Consumer Information (Wolters Kluwer)
• Zolmitriptan Disintegrating Tablets Consumer Information (Wolters Kluwer)
• Zolmitriptan Spray Consumer Information (Wolters Kluwer)
• Zolmitriptan Consumer Information (Cerner Multum)
• Zolmitriptan nasal Consumer Information (Cerner Multum)
• Zolmitriptan Advanced Consumer Information (Micromedex)
• Zolmitriptan AHFS DI Monographs (ASHP)